These results highlight semaglutides early action on decreasing major cardiovascular events, with significant benefits already evident by the first six months, and for some, even earlier, even before any major weight loss and before most patients would have been titrated to their full target dose of 2.4 mg, lead author Jorge Plutzky, MD, director of preventive cardiology with Brigham and Womens Hospital, said in a statement
Drawing 5 extra units (0.05 ml) on a syringe means you just took an extra 1.0 mg of tirzepatide
Additionally, tirzepatide acts on central appetite regulation pathways in the hypothalamus, leading to reduced caloric intake and significant weight loss
Retrieved from Malaeb, S., Perez-Leighton, C
Novo Nordisks success is a testament to the transformative impact GLP-1 drugs are having on health, food consumption, and overall market dynamics